Pancreatic Cancer Research

ResearcherUtrecht UniversityActive in the last 2 years

Babs M. Zonderhuis

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1383-7021; OpenAlex author ID A5066629527. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 3 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 3 papers · 2026: 2 papers

Papers 15

  1. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  2. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  3. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  4. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Co-author DOI 10.1097/sla.0000000000006910↗
  5. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  6. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Last author DOI 10.1001/jamasurg.2023.7872↗
  7. Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy: A Single-Center Experience. Co-author DOI 10.1245/s10434-024-15591-4↗
  8. Practice variation in venous resection during pancreatoduodenectomy for pancreatic cancer: A nationwide cohort study. Co-author DOI 10.1016/j.surg.2023.06.012↗
  9. The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periampullary Diseases, a Novel A… Co-author DOI 10.3390/cancers14020344↗
  10. Venous wedge and segment resection during pancreatoduodenectomy for pancreatic cancer: impact on short- and long-term outcomes in a nationwide cohort analysis. Co-author DOI 10.1093/bjs/znab345↗
  11. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreati… Co-author DOI 10.1186/s12885-021-08031-z↗
  12. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Stu… Co-author DOI 10.1148/radiol.2019191109↗
  13. Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled t… Co-author DOI 10.1186/s13063-020-4180-z↗
  14. Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach. Co-author DOI 10.1634/theoncologist.2019-0680↗
  15. Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study. Co-author DOI 10.1148/radiol.2016152835↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 8 shared papers, 2017–2025 · strength 0.96
  2. Geert Kazemier M · 7 shared papers, 2017–2025 · strength 0.87
  3. Bas Groot Koerkamp · 5 shared papers, 2021–2025 · strength 0.65
  4. Ignace H. J. T. de Hingh · 5 shared papers, 2021–2025 · strength 0.65
  5. Bert A. Bonsing · 5 shared papers, 2021–2025 · strength 0.65
  6. Hjalmar C. van Santvoort · 5 shared papers, 2021–2025 · strength 0.65
  7. Casper H.J. van Eijck · 5 shared papers, 2021–2025 · strength 0.65
  8. Johanna W. Wilmink · 4 shared papers, 2021–2025 · strength 0.59
  9. Vincent B. Nieuwenhuijs · 4 shared papers, 2021–2025 · strength 0.55
  10. J. Sven D. Mieog · 4 shared papers, 2021–2025 · strength 0.55
  11. Judith de Vos‐Geelen · 4 shared papers, 2021–2025 · strength 0.48
  12. Freek D. Daams · 4 shared papers, 2017–2024 · strength 0.45
  13. Gijs A. Patijn · 3 shared papers, 2021–2025 · strength 0.42
  14. Geertjan van Tienhoven · 3 shared papers, 2021–2025 · strength 0.42
  15. Jacob L. van Dam · 3 shared papers, 2021–2025 · strength 0.42
  16. Quisette P. Janssen · 3 shared papers, 2021–2025 · strength 0.42
  17. Marion B.M. van der Kolk · 3 shared papers, 2021–2025 · strength 0.42
  18. Marjolein Y.V. Homs · 3 shared papers, 2021–2025 · strength 0.42
  19. Martijn W.J. Stommel · 3 shared papers, 2021–2025 · strength 0.38
  20. Rutger T. Theijse · 2 shared papers, 2024–2025 · strength 0.34
  21. Thomas F. Stoop · 2 shared papers, 2024–2025 · strength 0.34
  22. Esther N. Dekker · 2 shared papers, 2025 · strength 0.32
  23. Stefan A.W. Bouwense · 2 shared papers, 2025 · strength 0.32
  24. Roeland F. de Wilde · 2 shared papers, 2025 · strength 0.32
  25. Laura L. Meijer · 2 shared papers, 2020–2022 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.